Skyrizi now PBS listed
For Fellows and Trainees
For Health Professionals
Posted 10 months ago
Skyrizi (risankizumab) is now Pharmaceutical Benefits Scheme listed for the treatment of severe chronic plaque psoriasis.
The drug is an interleukin 23 (IL-23) inhibitor and is indicated for treatment in adults who are candidates for phototherapy or systemic therapy.
Please review the Consumer Medicines Information here for further safety information.